Monthly Archives: June 2021

Exclusive Data for Progress poll: Wiley in second behind Adams – City & State

Posted: June 20, 2021 at 1:00 am

As New York City progressives urge consolidation around Maya Wiley in the Democratic mayoral primary, a new poll from progressive think tank Data for Progress shows her in second place in the race, trailing just Brooklyn Borough President Eric Adams.

The poll shared exclusively with City & State shows Adams in first place, as 26% of likely Democratic primary voters top choice, Maya Wiley, former counsel to Mayor Bill de Blasio, in second, with 20%, Andrew Yang, the entrepreneur and former presidential candidate, in third with 16% and Kathryn Garcia, the former New York City sanitation commissioner, in fourth with 14%. All other candidates are in the single digits. The text message poll of 998 likely voters was conducted between June 7-13. That followed a period when prominent progressive elected officials and organizations lined up behind Wiley alone. Reps. Alexandria Ocasio-Cortez and Jamaal Bowman and state Sen. Julia Salazar all endorsed Wiley between June 4-5, and on June 4 the New York Working Families Party said Wiley would be the only mayoral candidate it would be supporting.

New York City Comptroller Scott Stringer lost major endorsements and support in the polls following accusations of sexual misconduct in 2001 and 1992, and former nonprofit executive Dianne Morales lost endorsements and grassroots support following complaints about working conditions on her campaign that led to a labor dispute and the firing of more than 50 campaign staffers. That has left Wiley as the last progressive standing, hoping to garner some of the energy that helped elect de Blasio in 2013 and has flipped so many legislative seats from moderate Democratic incumbents to more progressive newcomers in the last few years.

Data for Progress is actively rooting for Wiley and against Adams, who is more conservative. After a volatile race for Mayor, Data for Progress polling shows that the race has narrowed and that Maya Wiley remains the only viable progressive who can win this race, Data for Progress Political Director Marcela Mulholland said in a statement emailed to City & State. In close second, Wiley has a window of opportunity to bring together a winning coalition ahead of next Tuesday and block Eric Adams, a veritable Republican whos looking out for the NYPD and corporate interests instead of working New Yorkers, from becoming Mayor.

Data for Progress had previously polled the mayors race between March 21-April 5, when it found Yang in first place as 26% of likely Democratic voters first choice, Adams in second with 13%, Stringer in third with 11% and Wiley in fourth with 10%.

With support from many major labor unions and elected officials and a massive campaign warchest buoyed by outside spending from super PACs, nearly every public poll of the mayoral race in the last six weeks has shown Adams leading. A WNBC/Telemundo 47/POLITICO/Marist Poll conducted from June 3-9 also released Monday showed Adams with a comfortable lead. Insiders were eagerly awaiting a poll from the trusted Marist Institute for Public Opinion, since many of high-profile pollsters have stayed away from the mayoral race, thinking it would be difficult to accurately poll the first citywide use of ranked-choice voting in New York. The Marist poll found Adams in first, as 24% of likely Democratic voters top choice, Garcia in second with 17%, Wiley in third with 15% and Yang in fourth, with 13%. All other candidates were in the single digits, and 13% of voters are still undecided ahead of election day on June 22.

Data for Progress also polled the comptroller race, finding New York Council Speaker Corey Johnson and City Council Member Brad Lander tied for first place, as 23% of likely Democratic voters top choice. However Johnson outperformed Lander when voters were asked for their second and third choices. Michelle Caruso-Cabrera, a former financial journalist, was in a distant third with 10% of voters top choices, and every other candidate was in single digits but 29% of voters were undecided. Public polling in the comptroller race has been limited, but this poll would be the best result for Lander by far. Lander has positioned himself as the most progressive candidate in the race. He has consolidated support on the left and has been running TV ads touting support from Ocasio-Cortez, New York City Public Advocate Jumaane Willians and U.S. Sen. Elizabeth Warren of Massachusetts.

Data for Progress is also releasing a text message and web poll of 642 likely Democratic voters in Manhattan, asking who they would vote for in the race for Manhattan district attorney, which will not use ranked-choice. Alvin Bragg, former chief deputy state attorney general and Tali Farhadian Weinstein, former general counsel to the Brooklyn district attorney, were tied for first with 26% each. Some 21% of voters were undecided and every other candidate was in single digits.

Farhadian Weinstein is running on a much more moderate platform than some of her competitors, including Bragg. Progressive activists including former state attorney general candidate Zephyr Teachout and former Manhattan district attorney candidate Janos Marton have urged Manhattanites who support progressive criminal justice reform to consolidate behind Bragg, though supporters of other progressive candidates in the field like civil rights attorney Tahnie Aboushi have pushed back. But just about every one of Farhadian Weinsteins opponents criticized her this past weekend after campaign finance filings revealed that she has donated $8.2 million of her own money to her campaign in the span of just two weeks. That massive sum was more than any other candidate had raised for the race in total. And Data for Progress is openly advocating against Farhadian Weinstein. Tali Farhadian Weinstein poured $8 million dollars of her own coin into her campaign for DA and still is only tied, DFP Executive Director Sean McElwee wrote in an emailed statement. Its clear that progressives have an obligation to consolidate and block Weinsteins Bloomberg-esque run for Manhattan DA and back Alvin Bragg, the only progressive positioned to beat Weinstein.

More here:

Exclusive Data for Progress poll: Wiley in second behind Adams - City & State

Posted in Progress | Comments Off on Exclusive Data for Progress poll: Wiley in second behind Adams – City & State

SocGen’s ALD Is Said to Progress in Talks on LeasePlan Deal – Bloomberg

Posted: at 1:00 am

Societe Generale SAs car leasing arm ALD SA is progressing in negotiations on a potential combination with competitor LeasePlan, people with knowledge of the matter said.

ALD is in bilateral talks with LeasePlans owners, an investor group led by buyout firm TDR Capital, about a deal, the people said. The French company has been conducting due diligence on LeasePlans business, according to the people, who asked not to be identified because the information is private.

LeasePlans private equity backers are considering options for the business ranging from a full to partial sale, Bloomberg News reported in March. Spanish lender Banco Santander SA was also evaluating LeasePlan earlier, people with knowledge of the matter have said.

A merger between LeasePlan and ALD, which manages nearly 1.8 million vehicles across 43 countries, could create a European vehicle leasing powerhouse. For Societe Generale, it would represent one of the French banks biggest bets in auto leasing since it began expanding into the market in the early 2000s.

Shares of ALD have risen 10% in Paris trading this year, giving the company a market value of about 5.1 billion euros ($6.2 billion). While the TDR consortium is currently focusing on discussions with ALD, other suitors could still emerge, the people said.

No final agreements have been reached, and talks could still fall apart, the people said. Representatives for ALD, Societe Generale and TDR declined to comment. A spokesperson for LeasePlan didnt immediately respond to a request for comment.

LeasePlan offers personal car leases and oversees corporate fleets. It manages about 1.7 million vehicles in more than 30 countries, according to its website. It reported about 9.85 billion euros of revenue last year, competing with the likes of ALD and BNP Paribas SAs Arval unit.

Leasing businesses can be highly profitable for lenders, with the potential to deliver better returns on equity than banking and trading units. Societe Generale has grown ALD in part through acquisitions and took the business public in 2017. The French lender owns about 80% of ALD, according to data compiled by Bloomberg.

A consortium including TDR, Abu Dhabi Investment Authority and an arm of Goldman Sachs Group Inc. agreed to buy LeasePlan for 3.7 billion euros in 2015. LeasePlans shareholders were seeking a valuation of around 7.5 billion euros from an aborted initial public offering in 2018.

With assistance by Geraldine Amiel

Before it's here, it's on the Bloomberg Terminal.

Visit link:

SocGen's ALD Is Said to Progress in Talks on LeasePlan Deal - Bloomberg

Posted in Progress | Comments Off on SocGen’s ALD Is Said to Progress in Talks on LeasePlan Deal – Bloomberg

Satellite photos show China’s progress on the new aircraft carrier expected to give its naval power a boost – Business Insider

Posted: at 1:00 am

A new satellite photo shows China making "substantial progress" on its newest aircraft carrier, according to a new analysis.

Photos of the new carrier, under construction at Jiangnan Shipyard in Shanghai, have been leaking out online over the past several weeks, some images clearer than others.

This week, the Center for Strategic and International Studies, a Washington, DC think tank, released an analysis of the carrier's development with high-resolution satellite photos of the new carrier from Maxar Technologies.

The Chinese navy has two aircraft carriers the Liaoning and Shandong. The first ship was built from the refitted hull of an older Soviet vessel, and the other is a Chinese-built copy of the first, with some improvements.

The third carrier, a still unnamed ship known as Type 003, is expected to "significantly upgrade China's naval capabilities," CSIS senior fellows Matthew Funaiole and James Bermudez Jr. and associate fellow Brian Hart wrote Tuesday in their satellite imagery analysis.

"When the Type 003 eventually enters service, it will be a formidable addition to China's navy and allow it to more effectively project power," they wrote.

Likely similar in size to the US Navy's Kitty Hawk-class carriers a decommissioned class of steam-powered flattops that were roughly 1,070 feet long the third carrier is expected to be the Chinese navy's largest surface warship, the CSIS experts assessed.

Additionally, the ship is expected to feature a smaller command center, or "island," and a much larger flight deck than its predecessors, freeing up space for a larger carrier air wing than the roughly 40 fixed-wing and rotary aircraft carried by the Liaoning and Shandong.

Though work on the flight deck is incomplete, there are indications that it will feature a more modern flat-top design, almost certainly with catapults, as opposed to the less efficient ski jumps seen on the other two carriers.

The ski jump design of the first two carriers has put limitations on how much weaponry and fuel the heavy J-15 carrier-based fighters can launch with, reducing the combat power of the carrier.

Steam catapults or the newer electromagnetic aircraft launch system would likely solve that problem, and they would also allow the carrier to launch larger aircraft like early warning planes able to boost situational awareness.

China's third carrier is expected to be conventionally-powered. There has, however, been speculation that follow-on carriers could be nuclear-powered, like the US Navy's current fleet of Nimitz- and Ford-class carriers.

The CSIS report said that progress on the carrier is moving at the same pace as the construction of the Shandong, suggesting that the new ship may not be launched until next year. It could then be several more years before China gets it fitted out, through sea trials, and commissioned into service.

"It is not a US carrier, as things are today," Funaiole recently told Insider, speaking of China's third aircraft carrier, "but it's still a huge step for China. It's impressive what they have been able to do in a short amount of time."

See the original post:

Satellite photos show China's progress on the new aircraft carrier expected to give its naval power a boost - Business Insider

Posted in Progress | Comments Off on Satellite photos show China’s progress on the new aircraft carrier expected to give its naval power a boost – Business Insider

Forward Progress Stopped Of Grass Fire That Threatened Structures, Forced Evacuations In Elk Grove – CBS Sacramento

Posted: at 1:00 am

ELK GROVE (CBS13) Crews on Wednesday put out a grass fire in Elk Grove that forced evacuations and threatened structures, the Cosumnes Fire Department said.

(credit: Cosumnes Fire Department)

The fire was along Sheldon Road between Waterman Road and Bradshaw Road. The fire burned about 73 acres and was threatening around 20 structures, officials said.

The department said at around 5 p.m. that forward progress of the fire was stopped. No homes were damaged or destroyed but officials said some outbuildings were burned.

Cosumnes Fire said evacuations were coordinated with Elk Grove police for the area.

A photo (right) from the fire department shows an aerial view of the burn area.

Cosumnes Fire said the grass fire was upgraded to two alarms and multiple resources were on the scene.

At this time, it is unclear what started the fire.

More here:

Forward Progress Stopped Of Grass Fire That Threatened Structures, Forced Evacuations In Elk Grove - CBS Sacramento

Posted in Progress | Comments Off on Forward Progress Stopped Of Grass Fire That Threatened Structures, Forced Evacuations In Elk Grove – CBS Sacramento

Proud Boys and Oath Keepers, Forceful on Jan. 6, Privately Are in Turmoil – The Wall Street Journal

Posted: at 12:59 am

The far-right group the Oath Keepers is splintering after board members accused the founder of spending its money on hair dye, steaks and guns. The leader of the Proud Boys, choked off from the financial system, is printing Black Lives Matter T-shirts to make money.

The finances of the two most visible groups with members involved in the Jan. 6 riot at the U.S. Capitol are sputtering. Leaders are low on cash, struggling with defections and arguing with members over the future.

The Oath Keepers and the Proud Boys have seen more than three dozen of their members or affiliates arrested in connection with Jan. 6. Prosecutors are investigating the money trail that led the groups to Washington that day and examining the roles played by the Proud Boys leader, Enrique Tarrio, and the founder of the Oath Keepers, Stewart Rhodes, neither of whom entered the Capitol building.

In late April, Federal Bureau of Investigation agents surrounded Mr. Rhodes in unmarked vehicles in Lubbock, Texas, seized his iPhone and served him a search warrant, said the Oath Keepers general counsel, Kellye SoRelle. The warrant sought evidence about any planning, preparation or travel to breach the Capitol on Jan. 6, including any tactical training or weapons procurement. His phone has since been returned.

Members of the Proud Boys and Oath Keepers appeared well-organized at the Capitol, some coordinating with walkie-talkies and wearing military-style outfits. Behind the facade of power is a yearslong cash crunch exacerbated by internal discord and isolation from financial firms and social media. Fallout from Jan. 6 made it all worse.

Continued here:

Proud Boys and Oath Keepers, Forceful on Jan. 6, Privately Are in Turmoil - The Wall Street Journal

Posted in Proud Boys | Comments Off on Proud Boys and Oath Keepers, Forceful on Jan. 6, Privately Are in Turmoil – The Wall Street Journal

CF Industries (CF) Stock Up 29% YTD: What’s Driving the Rally? – Yahoo Finance

Posted: at 12:59 am

CF Industries Holdings, Inc.s CF shares have gained 29.1% so far this year. The company has also outperformed its industrys rise of 19.7% over the same time frame. Moreover, it has topped the S&P 500s 12.4% rise over the same period.

Lets take a look into the factors behind this Zacks Rank #1 (Strong Buy) stocks price appreciation.

Zacks Investment Research

Image Source: Zacks Investment Research

Strong demand of nitrogen fertilizer, higher nitrogen prices and upbeat outlook have contributed to the rally in the companys shares.

CF Industries is benefiting from higher nitrogen prices as witnessed in the first quarter of 2021. The companys average selling prices in the quarter were higher on a year-over-year basis across most segments due to lower global supply availability.

The company expects nitrogen pricing to be positive in 2021 as global nitrogen supply and demand balance has been significantly tightened by low global coarse grains stocks-to-use ratios as well as higher energy prices in Asia and Europe. As such, higher nitrogen prices are expected to drive the companys sales and bottom line.

Moreover, CF Industries should gain from higher nitrogen fertilizer demand in major markets. Global nitrogen demand is expected to remain strong this year. Strong crop commodity prices are contributing to higher demand globally. Industrial demand has also recovered from the pandemic-related disruptions.

The company, in its first-quarter call, said that it sees around 90-92 million planted corn acres in the United States in 2021. It also expects higher canola plantings in Canada to support nitrogen demand. Moreover, CF Industries projects higher nitrogen demand in North America for industrial uses. The company anticipates nitrogen requirements in other regions to remain strong this year, which is likely to be driven by strong demand for urea imports from India and Brazil.

Story continues

CF Industries Holdings, Inc. Price and Consensus

CF Industries Holdings, Inc. price-consensus-chart | CF Industries Holdings, Inc. Quote

Other top-ranked stocks worth considering in the basic materials space include Nucor Corporation NUE, Cabot Corporation CBT and Impala Platinum Holdings Limited IMPUY.

Nucor has a projected earnings growth rate of 285.3% for the current year. The companys shares have surged around 123% in a year. It currently sports a Zacks Rank #1. You can see the complete list of todays Zacks #1 Rank stocks here.

Cabot has an expected earnings growth rate of around 126% for the current fiscal. The companys shares have rallied 55% in the past year. It currently carries a Zacks Rank #2 (Buy).

Impala Platinum has an expected earnings growth rate of 225.2% for the current fiscal. The companys shares have surged around 137% in the past year. It currently carries a Zacks Rank #2.

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that its poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Nucor Corporation (NUE) : Free Stock Analysis Report

CF Industries Holdings, Inc. (CF) : Free Stock Analysis Report

Cabot Corporation (CBT) : Free Stock Analysis Report

Impala Platinum Holdings Ltd. (IMPUY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Read more:

CF Industries (CF) Stock Up 29% YTD: What's Driving the Rally? - Yahoo Finance

Posted in Cf | Comments Off on CF Industries (CF) Stock Up 29% YTD: What’s Driving the Rally? – Yahoo Finance

Healthy Participants Dosed in Trial of Investigational CF Therapy EDT001 – Cystic Fibrosis News Today

Posted: at 12:59 am

The first participants have been dosed in the first clinical trial testing EDT001, an investigational therapy for cystic fibrosis (CF) being developed by Enterprise Therapeutics.

The trial is being conducted in healthy participants (without CF) to assess the investigational medicines safety profile.

We are excited to be entering the clinic with ETD001, John Ford, PhD, Enterprises CEO, said in a press release.

CF is caused by mutations in the CFTR gene that provides instructions for making the CFTR protein, which regulates the transport of water and salts in and out of cells. One of the hallmark consequences of CFTR dysfunction in CF is the formation of abnormally thick mucus, which impairs the function of the lungs and other organs, and provides a breeding ground for infectious bacteria.

ETD001 is designed to target a protein called epithelial sodium ion channel, or ENaC. Like the CFTR protein, ENaC helps to coordinate the amount of water and other substances present in mucus.

By targeting ENaC, EDT001 aims to increase the amount of water in the mucus, making it less thick. This could improve lung function and life quality, and reduce the frequency of lung infections, in people with CF.

According to Ford, EDT001 has best-in-class potential due to its long duration of action in the lung and favourable pre-clinical safety profile.

The investigational therapy could significantly improve quality of life for people living with cystic fibrosis and other respiratory diseases linked to mucus obstruction, Ford said.

Notably, because it targets the ENaC protein, EDT001 is expected to work equally well in all people with CF, regardless of which type of CFTR mutation they have. This sets EDT001apart from other CF treatments, such as CF modulators a therapy class that works to correct the function of the CFTR protein in people with specific mutations.

ENaC inhibition via ETD001 shows great promise in providing a therapeutic option for the many people with cystic fibrosis who are not genetically suited to or fail to benefit from CFTR modulators, said David Morris, MD, chief medical officer at Enterprise.

We look forward to generating our first data in human volunteers under this program, Morris said.

Originally posted here:

Healthy Participants Dosed in Trial of Investigational CF Therapy EDT001 - Cystic Fibrosis News Today

Posted in Cf | Comments Off on Healthy Participants Dosed in Trial of Investigational CF Therapy EDT001 – Cystic Fibrosis News Today

Inter Miami CF Midfielder Lewis Morgan On The Need To Improve – CBS Miami

Posted: at 12:59 am

MIAMI (CBSMiami) Inter Miami CF midfielder Lewis Morgan sat down for an interview with CBS4 Mike Cugno, to speak about the current season and what the team needs to do to improve.

Q: I saw in an interview your bucket list item is to go sky diving. So, lets start there. Have you been able to jump out of a plane yet?

A: No not yet. I dont actually know how the football club would take me doing that at the moment. So yea just a lot of golf at the moment in my spare time. Ill have plenty of time for sky diving once I hang up the boots.

Morgan hasnt taken that big leap of faith just yet. But he dove right into a young franchise and became a household name last year, scoring 5 goals and recording 8 assists. He earned team MVP honors.

Q: Were you surprised or you just knew you had that in you and you were ready for a big year?

A: I think thats probably a good way to put it I was definitely ready for a big year. I had a couple of years of not disappointments as such but maybe frustrations of not playing at levels I knew I was capable of. It was something when I signed with the club it was a goal that I had in mind. Its a goal that I have, not just as a year objective, but every day in training I want to be the best player.

Now, as one of the best players for the club, Morgan has to identify why theyve gotten off to a slow start, losing 4 of their first 8 matches of their second season. He says talent is there but theattitude has to follow.

What are we like when the game goes against us? And recently when weve maybe had a setback we havent really bounced back having won. These little things that we are trying to help to do better and Ive seen a great reaction from the team. We obviously had a bounce-back game behind closed doors against Toronto and the guys looked great. Its just about taking our training performances into games and really having that belief, said Morgan.

As Morgan mentioned, Inter Miami recently beat Toronto in a closed-door scrimmage. Theyre hoping to use that as a jumping-off point for the next part of their season.

Having these few weeks to really focus on improving and taking what we achieved in the first 8 games of the season, the games weve done well in, and why weve done well in those games and try to replicate that going forward. I think weve made the best use of the time afforded to us and I think were just looking forward to getting back to the games and hopefully righting some wrong of the previous DC game.

Read more from the original source:

Inter Miami CF Midfielder Lewis Morgan On The Need To Improve - CBS Miami

Posted in Cf | Comments Off on Inter Miami CF Midfielder Lewis Morgan On The Need To Improve – CBS Miami

Is CF Industries Holdings, Inc. (CF) Stock at the Top of the Agricultural Inputs Industry? – InvestorsObserver

Posted: at 12:59 am

The 60 rating InvestorsObserver gives to CF Industries Holdings, Inc. (CF) stock puts it near the top of the Agricultural Inputs industry. In addition to scoring higher than 78 percent of stocks in the Agricultural Inputs industry, CFs 60 overall rating means the stock scores better than 60 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

CF Industries Holdings, Inc. (CF) stock is trading at $48.86 as of 1:38 PM on Friday, Jun 18, a drop of -$1.15, or -2.3% from the previous closing price of $50.01. The stock has traded between $48.67 and $50.15 so far today. Volume today is 1,653,255 compared to average volume of 2,111,996.

Click Here to get the full Stock Score Report on CF Industries Holdings, Inc. (CF) Stock.

Read the original here:

Is CF Industries Holdings, Inc. (CF) Stock at the Top of the Agricultural Inputs Industry? - InvestorsObserver

Posted in Cf | Comments Off on Is CF Industries Holdings, Inc. (CF) Stock at the Top of the Agricultural Inputs Industry? – InvestorsObserver

RNA-based Therapies Show Promise in Early Studies, ReCode Reports – Cystic Fibrosis News Today

Posted: at 12:59 am

RCT223 and RTX0001, ReCode Therapeutics experimental RNA-based therapies for cystic fibrosis (CF), safely restored function to CFTR, the faulty protein in CF, in patient-derived lung cells.

Delivered through the companys non-viral platform called the selective organ targeting (SORT) lipid nanoparticle (LNP) platform the therapies were also found to be well-tolerated in lung cells from patients and in mice.

Our RNA-based approaches and broad LNP platform enable us to tackle CF from multiple angles in order to specifically target the underlying causes of the disease and maximally help patients, David Lockhart, PhD, ReCodes CEO and president, said in a press release.

These data showcase the potential of our differentiated RNA-based molecular therapies to treat cystic fibrosis, Lockhart said, adding that they are an important step as the company advances its CF program closer to studies in people.

ReCode plans to apply to the U.S. Food and Drug Administration in 2022, seeking the agencys clearance to start clinical trials of these therapies in the U.S.

The preclinical findings were presented by Michael Torres, PhD, the vice president of Recodes research and development, at the 44th European Cystic Fibrosis Conference held virtually June 912.

The oral presentation was titled Rescue of CFTR function in primary bronchial epithelial cells from patients with cystic fibrosis using lipid nanoparticle delivery of RNA-based therapies.

In people with CF, mutations in the CFTR gene impair the production of a functional CFTR, a protein channel that controls the flow of water and salts through cells, triggering the mucus in various organs to become thick and sticky.

ReCodes CF program, supported by a grant from the Cystic Fibrosis Foundation, is focused on treating the 1013% of CF patients who have nonsense mutations and limited therapeutic options.

Nonsense mutations introduce a premature stop signal in CFTRs DNA sequence, leading to the production of a shorter, non-functional CFTR protein.

The CF program currently comprises two RNA-based therapies delivered through the companys SORT LNP platform, which uses tiny non-viral fat (lipid) particles to transport and deliver their cargo to targeted organs.

The companys lead candidate, RCT223, uses a transfer RNA (tRNA) molecule which plays a role in the process of protein production to replace the premature stop signal with a go sequence in the CFTR gene, so that the full CFTR protein can be produced.

Newly presented data showed that both single and repeated dosing of RCT223 restored CFTR function in lung cells derived from CF patients and grown in the lab, a gold-standard cell model of CF.

This effect lasted for at least 72 hours (three days) after a single administration, and CFTR functional levels continued to rise with twice-weekly doses.

ReCodes mRNA replacement agent for CF, RTX0001, is designed to deliver to cells a working version of CFTRs messenger RNA molecule (mRNA), the intermediate molecule derived from DNA that guides protein production.

As such, RTX0001 is expected to increase the production of a working CFTR protein.

Preclinical data showed that RTX0001, delivered through a commercially available mesh nebulizer, successfully delivered CFTRs healthy mRNA into patient-derived lung cells and into the lungs of mice.

The delivered mRNA was found to effectively and significantly increase the production of a working CFTR after a single, low dose, and CFTRs activity was sustained for at least 72 hours after twice-weekly administration.

Both RNA-based therapies were generally well-tolerated in the evaluated preclinical models.

By leveraging our LNP platform to deliver genomic medicines, we have demonstrated the ability to restore cystic fibrosis transmembrane conductance regulator (CFTR) function through both tRNA and mRNA approaches, Lockhart said.

The companys pipeline also includes potential RNA-based therapies for primary ciliary dyskinesia (PCD), a genetic condition that impairs the function of lung cilia the fingerlike projections in the airways leading to chronic respiratory infections.

ReCode raised $80 million to support the preclinical development of its CF and PCD programs in April 2020.

See the rest here:

RNA-based Therapies Show Promise in Early Studies, ReCode Reports - Cystic Fibrosis News Today

Posted in Cf | Comments Off on RNA-based Therapies Show Promise in Early Studies, ReCode Reports – Cystic Fibrosis News Today